Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 48.6% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price traded down 48.6% on Monday . The company traded as low as $0.18 and last traded at $0.22. Approximately 191,793,903 shares traded hands during mid-day trading, an increase of 77% from the average daily volume of 108,651,023 shares. The stock had previously closed at $0.43.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Sunday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company has a market cap of $39.25 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.27.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.